AMEX Biotech Boxes Index (BTD)

Benzinga  Jun 29  Comment 
AbbVie Inc. (NYSE: ABBV) revealed that the Food and Drug Administration granted a fourth Breakthrough Therapy Designation (BTD) for its ibrutinib (IMBRUVICA) as a potential treatment of chronic graft-versus-host-disease (cGVHD) after failure of...
FierceBiotech  Aug 24  Comment 
Just weeks after announcing promising trial data, South San Francisco-based Exelixis says that the FDA has provided its breakthrough therapy designation for cabozantinib (approved as Cometriq) as a second-line treatment for kidney cancer.
FierceBiotech  Apr 8  Comment 
The FDA notified Merck execs last January that it was stripping away its breakthrough therapy designation for their closely watched hepatitis C combo. But the agency has now relented and reversed itself, in part, and the pharma giant today notes...
SeekingAlpha  Aug 22  Comment 
By Trevor Lowenthal: I recently conducted an email interview with Chief Operations Officer, Peter Culpepper of Provectus Pharmaceuticals (NYSEMKT:PVCT). The company operates within the biopharmaceutical industry, has roughly a $162 million market...
SeekingAlpha  May 27  Comment 
By Trust Intelligence: INTRODUCTION Provectus Biopharmaceuticals (PVCT) has been in the news much more than usual lately. The company has been the target of a number of negative articles in recent days, prompting increased stock price volatility...
SeekingAlpha  May 27  Comment 
By The Pump Stopper: I am reiterating my STRONG SELL rating on shares of Provectus (PVCT), as I still believe this stock has $0 intrinsic value and the fundamentals appear to be deteriorating. My opinion is that shares of PVCT, when unhalted,...
FierceBiotech  Jan 6  Comment 
A year after the FDA began to roll out the first of its breakthrough drug designations, the analysts at Leerink Swann have concluded that while the jury is still out on whether or not a BTD will mean a significantly shortened path to the...
FierceBiotech  Sep 17  Comment 
The BTD announcement marks another step forward in Boehringer's considerable effort to push a small group of late-stage cancer therapies into the market.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki